Compositions and methods for synthesizing 5′-capped RNAs

Inventors

Hogrefe, Richard I. • Lebedev, Alexandre • McCaffrey, Anton P. • Shin, Dongwon

Assignees

Trilink Biotechnologies LLC

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12103944-B2

Patent

Publication Date

2024-10-01

Expiration Date


Abstract

Provided herein are methods and compositions for synthesizing 5′Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2′Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.

Core Innovation

The invention relates to compositions and methods for synthesizing 5′-capped RNAs by using initiating capped oligonucleotide primers having a cap-containing primer structure of the form m7Gppp[N2′Ome]n[N]m, where m7G is N7-methylated guanosine or a guanosine analog. The primer structure is defined by nucleotide-base and modification variables and allows selection of cap and 2′-O-methylation patterns including Cap 0, Cap 1, Cap 2, and TMG-cap. The primer structure enables an inverted 5′-5′ cap arrangement as part of the initiating capped oligonucleotide primer.

The disclosure covers RNA molecules that contain such initiating capped oligonucleotide primers and pharmaceutical compositions comprising the RNA molecules and pharmaceutically acceptable carrier. The document also covers cells expressing proteins from the RNA molecules, thereby linking the capped RNA products to expression outcomes. Optional detectable markers and linkers are described as part of the primer designs within the defined formula structure.

The patent rationale states that the primer design addresses limitations of prior art by reducing the need for separate capping and 2′-O-methylation steps and by reducing bidi-initiation and heterogeneous 5′-ends. The document includes experimental rationale and performance expectations, including capping efficiency and fidelity, improved yields, and translation activity in cells.

Claims Coverage

The provided independent claim set is directed to a compound of a specified structural formula, or a salt, with defined variable selections, and dependent claims further narrow the compound and extend coverage to RNA molecules, cells, and pharmaceutical compositions. The main inventive features are the defined compound structure constraints and the extensions to RNA and formulation contexts.

Nucleoside base compound with defined R1 and R2

A compound of the following formula, or a salt thereof, wherein B1 and B2 are each independently an unprotected nucleoside base, R1 is CH3, and R2 is H or CH3.

Naturally occurring nucleoside base selection for B1 and B2

The compound wherein B1 and B2 are each independently naturally occurring nucleoside bases.

Specific base set for B1 and B2

The compound wherein B1 and B2 are independently selected from adenine, guanine, and N6-methyladenine.

Fixed methyl substitution at R2

The compound wherein R2 equals CH3.

RNA molecule containing the defined compound

An RNA molecule comprising the compound defined by the specified formula.

Pharmaceutical composition with RNA and pharmaceutically acceptable carrier

A pharmaceutical composition comprising the RNA molecule and a pharmaceutically acceptable carrier.

Overall, the claim coverage focuses on a defined nucleoside-based compound structure, narrows nucleoside base selections, and extends the scope to RNA molecules containing the compound and to pharmaceutical compositions comprising such RNA with a pharmaceutically acceptable carrier.

Stated Advantages

Reduced need for separate capping and 2′-O-methylation steps.

Reduced bidi-initiation and heterogeneous 5′-ends.

Higher capping efficiency and fidelity.

Improved yields, including greater mg/mL yields.

Demonstrated increased translation activity in cells for luciferase mRNA.

Documented Applications

Synthesizing 5′-capped RNAs using initiating capped oligonucleotide primers with defined cap-containing primer structures.

Providing RNA molecules that contain the initiating capped oligonucleotide primer structure for expression of proteins in cells.

Use in pharmaceutical compositions comprising the capped RNA molecule and a pharmaceutically acceptable carrier.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.